Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Common Equity (2023 - 2025)

Zhengye Biotechnology Holding has reported Common Equity over the past 3 years, most recently at $35.2 million for Q4 2025.

  • Quarterly Common Equity fell 10.89% to $35.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.2 million through Dec 2025, down 10.89% year-over-year, with the annual reading at $43.9 million for FY2025, 12.73% up from the prior year.
  • Common Equity was $35.2 million for Q4 2025 at Zhengye Biotechnology Holding, down from $41.7 million in the prior quarter.
  • Over five years, Common Equity peaked at $47.1 million in Q4 2023 and troughed at $35.2 million in Q4 2025.
  • The 3-year median for Common Equity is $40.6 million (2024), against an average of $40.9 million.
  • Year-over-year, Common Equity decreased 16.11% in 2024 and then dropped 10.89% in 2025.
  • A 3-year view of Common Equity shows it stood at $47.1 million in 2023, then fell by 16.11% to $39.5 million in 2024, then fell by 10.89% to $35.2 million in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Common Equity are $35.2 million (Q4 2025), $41.7 million (Q2 2025), and $39.5 million (Q4 2024).